<DOC>
	<DOCNO>NCT00002801</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug combine radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness combination chemotherapy consist fluorouracil-uracil leucovorin plus radiation therapy treat patient colorectal cancer undergone surgery remove tumor .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose-limiting toxicity postoperative fluorouracil-uracil plus leucovorin calcium concurrently radiotherapy patient colorectal cancer . II . Determine toxicity regimen patient . III . Determine response tumor patient measurable disease treat regimen . OUTLINE : This dose-escalation study fluorouracil-uracil ( UFT ) . Beginning within 10 week definitive surgery , patient receive oral UFT oral leucovorin calcium ( CF ) 3 time day day 1-28 . Treatment continue every 5 week 2 course absence disease progression unacceptable toxicity . Beginning day 1 second course , patient undergo radiotherapy tumor bed involved lymph node 5 day week 5 week , follow boost radiotherapy primary tumor bed 5-16 day . Patients receive 3 additional course UFT plus CF begin 4 week completion radiotherapy recovery toxic effect UFT , whichever occurs later . Patients measurable disease ongoing response fifth course receive additional course UFT CF . Cohorts 3-6 patient receive escalate dos UFT second course maximum tolerate dose ( MTD ) determine . The MTD define high dose minority patient experience dose-limiting toxicity . Patients follow every 3 month 1 year discretion investigator . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Tegafur</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis colorectal cancer postoperative radiotherapy pelvis indicate PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 4,000/mm3 Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL ALT great 1.25 time upper limit normal ( ULN ) ( great 5 time ULN elevation secondary malignancy ) Alkaline phosphatase great 1.25 time ULN ( great 5 time ULN elevation secondary malignancy ) Renal : Creatinine normal OR Creatinine clearance normal great 60 mL/min Other : No medical psychiatric condition would preclude study No prior malignancy except : Appropriately treat localized epithelial skin cervical cancer Remote history cure malignancy ( discretion sponsor ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent antineoplastic biological response modifier Chemotherapy : No prior systemic chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy pelvis Surgery : See Disease Characteristics Other : No concurrent investigational drug No concurrent antineoplastic therapy No concurrent halogenated antiviral agent ( e.g. , sorivudine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
</DOC>